Patent intelligence · US
US 11096966
Cell preparations for extemporaneous use, useful for healing and rejuvenation in vivo
Cell preparations for extemporaneous use, useful for healing and rejuvenation in vivo
Patent details — US 11096966
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 24, 2021
- Expiration
- Aug 19, 2041
- Applicant
- RegenLab USA LLC
- Claims
- 15
- CPC classes
- A61K, A61K2300/00, A61K2800/87, A61K35/14
Quick answer
US 11096966 (Cell preparations for extemporaneous use, useful for healing and rejuvenation in vivo) is held by RegenLab USA LLC. Status: granted. Granted Aug 24, 2021. Expires Aug 19, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- RegenLab USA LLC
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61K, A61K2300/00, A61K2800/87, A61K35/14, A61K35/15, A61K35/16
More from RegenLab USA LLC
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 11096966?
US 11096966 (Cell preparations for extemporaneous use, useful for healing and rejuvenation in vivo) is held by RegenLab USA LLC. Status: granted. Granted Aug 24, 2021. Expires Aug 19, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11096966?
RegenLab USA LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 11096966 expire?
Our index shows an expiration date of Aug 19, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.